ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,613.37
      -0.38%
      US Tech 100
      18,993.40
      -1.08%
      Dow Jones
      41,221.68
      0.11%
      Brent Oil
      80.245
      2.39%
      Bitcoin
      63,358.16
      -1.55%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. INmune Bio Inc (INMB)

      7. INmune Bio Inc (INMB) News

      INMB

      INmune Bio (INMB)

      INmune Bio Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INMB
      DateTimeSourceHeadlineSymbolCompany
      2:03PMiHub NewswireFeaturedELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET
      08/09/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      08/09/20244:00PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INMBINmune Bio Inc
      08/08/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INMBINmune Bio Inc
      08/02/20244:01PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:INMBINmune Bio Inc
      08/02/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      08/01/20244:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INMBINmune Bio Inc
      07/30/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      07/19/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      06/13/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      06/12/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      05/30/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      05/30/20248:00AMGlobeNewswire Inc.INmune Bio Inc. to Join Russell 3000® IndexNASDAQ:INMBINmune Bio Inc
      05/29/20244:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:INMBINmune Bio Inc
      05/23/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      05/16/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      05/16/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      05/16/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      05/16/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      05/16/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      05/09/20244:05PMGlobeNewswire Inc.INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateNASDAQ:INMBINmune Bio Inc
      05/07/20248:00AMGlobeNewswire Inc.INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9NASDAQ:INMBINmune Bio Inc
      04/30/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsNASDAQ:INMBINmune Bio Inc
      04/29/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
      04/25/20249:00AMGlobeNewswire Inc.INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:INMBINmune Bio Inc
      04/23/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayNASDAQ:INMBINmune Bio Inc
      04/22/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingNASDAQ:INMBINmune Bio Inc
      04/08/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024NASDAQ:INMBINmune Bio Inc
      03/28/20244:01PMGlobeNewswire Inc.INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateNASDAQ:INMBINmune Bio Inc
       Showing the most relevant articles for your search:NASDAQ:INMB